Oferta tecnológica / Spin-offs

Spin-Off technology-based companies:

Seqplexing is a company created in 2013, which was born from the idea of generating solutions for research and clinical applications, using as a basis the introduction of new advanced genetic techniques and platforms, mainly next generation sequencing (NGS). Seqplexing aims to cover the need for reliable protocols for the sequencing of amplicons or genes. To this end, it develops closed solutions that are easy to use and implement in its own laboratories.

Seqplexing’s mission is focused on providing a service to those laboratories that, due to their daily routine, do not have time to carry out the development of suitable protocols for the sequencing of genes or regions of interest. Seqplexing is transforming into a commercial kit all the necessary elements to carry out these techniques, providing a comprehensive service from the beginning of the sample preparation to the final analysis of the results.

Epidisease was created in 2014 because of a project led by INCLIVA researchers and the Center for Biomedical Research Network (CIBER) of Rare Diseases to transfer knowledge in the field of epigenetics and biomedical sciences to the service of society.

Epigenetics studies all those factors and mechanisms involved in the control of gene expression. The importance of this science is growing, as demonstrated by some of the conclusions of the Human Genome Project, thanks to which scientist have realised that the molecular bases of cellular functioning, development, ageing and many diseases goes far beyond the DNA sequence. Proof of this are recent findings from the Epigenome Road Map project.

Epidiseases’s mission is to leverage its expensive expertise in the field of epigenetics to provide its customers with biomedical solutions, diagnostic tools and new therapies, as well as to stimulate translational research with the goal of improving people’s health and well-being.

Nela BioDynamics is a young technology development company in biomedicine, which arises from Valencian university collaboration, formed by a group of multidisciplinary researchers with expertise in biomedicine and engineering. The company arises from the results of a master’s Thesis in Biomedical Engineering, which led to the obtaining of two patents on a novel intramedullary fixation device for joint arthroplasty, nails for fractures and exo-prosthetization; and a percutaneous collar for ostomies.

NELA spinal implant technology allows for a customised fit for each patient and avoids conventional techniques based on impact pressure fitting or the use of bone cement to achieve fixation. All this translates into a shorter surgical time, less pain, higher success rates and better quality of life for the patient. NELAS’s mission is to respond to different unmet medical need, while providing a positive socio-economic impact.

ARTHEx BIOTECH is a spin-off company of the University of Valencia that develops advanced RNA treatments against genetic diseases. The team has a solid experience in drug discovery and the involvement of microRNAs in neuromuscular diseases. They are supported by world-renowned scientific and clinical advisors who will facilitate the successful development of their products.

ARTHEx Biotech mission is to find effective treatments for unmet medical needs. The company’s first objective will be to investigate anti-miRNAs for the treatment of myotonic dystrophy type 1 (DM1), which is an orphan disease affecting more than 900 000 people worldwide (estimated prevalence 1/8000).

• Innovation policy
• R&D&I vision and strategy
• Innovation guidelines